Castor adds to its existing decentralized and hybrid clinical trial solutions platform to collect RWE, expand trials to global populations, and integrate virtual trial visits.
The company updates its platform to allow sites to review upcoming trial opportunities and apply for the ones that are suitable for them and their patients.
The first oral antibiotic treatment for urinary tract infections in over 20 years appears to be possible, after interim analysis advised for trials to be stopped after endpoints were met.
CVS Health and Walgreens announce that they will settle all opioid claims against them by US states, while it is reported that Walmart will do the same.
Oracle and ObvioHealth collaborate on clinical trial solutions using ObviGo to establish a “more complete clinical research ecosystem” in Asia Pacific region.
Clinical trial participants are traveling further to attend study sites than previously thought, according to Greenphire’s analysis of its payment data.
Medable announces the launch of a ‘patient-first’ oncology service that the company states will improve patient access, enrolment, and retention for clinical trials.
A $114m diversity in clinical trials initiative supported by the Bristol Myers Squibb Foundation (BMSF) and Gilead Sciences has selected 64 physicians for awards.
Altasciences is expanding its facility in Columbia, Missouri to provide bioanalytical services in support of preclinical and clinical studies conducted in the US.
The Association of Clinical Research Organizations (ACRO) has released a question and answer document to support the adoption of decentralized clinical trials (DCT).
Thermo Fisher’s clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
The company will split into two separate entities, one will focus on the development of neuroscience therapies and the other will become a standalone CDMO.
The long-running case relates to the change of formulation to its Levothyrox product, specifically the information the company provided when the product was altered.
CPhI Frankfurt takes place next week: covering the full supply chain from research and manufacturing to packaging and finished products. Here’s five ideas on how to make the most of the event.
A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
The company opens a bioanalytical lab in the US, which offers an additional 59,000-square-feet of space to the overall facility, making it “one of the largest laboratories of its kind.”
ConcertAI has introduced a digital trial solution informed by its collaboration with Bristol Myers Squibb to simplify patient identification, consent, IRB approval, and contract negotiations.
Clinical software surveillance company launched automated patient identification solution to bolster patient enrollment and reduce staff time needed to screen patients.
A federal judge in the Southern District of Florida has sentenced two Florida women to prison for their part in a conspiracy to falsify clinical trial data.
Updated interim results from Part A the RINGSIDE pivotal Phase 2/3 study of the company’s AL102 new drug showed consistent early tumor shrinkage with measures deepening over time, plus good tolerability at all doses.
Cardiff-based CatSci is investing in its oligonucleotides capability that will enable the company to make oligos from nanomole quantities up to 30 grams using solid phase synthesis.
Digital enrollment for Lark Health’s Cardiovascular Disease DCT is sped up by using the “tapestry of the entire internet” through Curavit and 1nHealth.
Sanofi has teamed up with TrialSpark to jointly acquire and advance clinical-stage candidates, leaning on its partner’s tech-enabled drug development capabilities to hustle the programs toward approval.
According to the agency, Teva communicated that it would have difficulties supplying immediate release formulations of the drug due to manufacturing delays.
